替米沙坦对慢性阻塞性肺疾病合并高血压患者血压和肺功能影响的临床观察

The Effects of Telmisartan to Blood Pressure Control and Pulmonary Function in COPD Patients Combine with Hypertension

目的慢性阻塞性肺疾病(COPD)患者约有30%合并高血压。本研究旨在探讨替米沙坦对慢性阻塞性肺疾病合并高血压患者血压及肺功能的影响,为该类患者选择用药提供参考。方法筛选符合COPD及高血压诊断的患者80例,按随机的方法分为替米沙坦治疗组和氨氯地平治疗组。在COPD传统治疗的基础上,替米沙坦治疗组应用替米沙坦进行降压治疗,氨氯地平组则以氨氯地平进行降压治疗。观察周期为24周,治疗前后观察患者的血压控制及肺功能(FEV1)情况。结果替米沙坦治疗组更有效地控制血压,且肺功能改善要优于氨氯地平组,P<0.05。结论 COPD合并高血压患者,替米沙坦有较好的疗效,无明显副作用,值得临床推广。

Object To explore the effects of Telmlsartan to the blood pressure and pulmonary function in COPD patients combine with hypertension. Methods 80 cases of COPD combine with hypertension patients divided into two groups randomly, the Telmisartan group and the Amlodipine group. Base the traditional treatment of COPD, the Telmisartan group were given the telmisartan in treating the hypertension and the Amlodipine group patients were given the Amlodipine in treating the hypertension. The observation time was 24 weeks, before and after treatment, the blood pressure level and the pulmonary function （FEV1） were observed. Results Compared with the Amlodipine group, Telmisartan treatment control the blood pressure and improved the pulmonary function more effectively, P 〈 0.05. Conclusion AS for patients combine with the COPD and the hypertension, Telmisartan has more pronounce effects in control the blood pressure and pulmonary function, and less side effects.